The Bureau of Internal Revenue (BIR) has issued Revenue Memorandum Circular (RMC) No. 27-2026, publishing the updated list of medicines exempt from 12-percent value-added tax (VAT), as endorsed by the Food and Drug Administration (FDA).
Released on April 8, 2026, the circular covers 2,263 VAT-exempt drugs under Republic Act (RA) No. 10963 or the Tax Reform for Acceleration and Inclusion (TRAIN) Act, and RA 11534 or the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act.
The Department of Health’s (DOH) FDA endorsed the updated list as part of ongoing efforts to ensure access to affordable medicines.
The move supports the directive of President Ferdinand R. Marcos Jr. to make healthcare more accessible to Filipinos.
BIR Commissioner Charlito Martin R. Mendoza said the issuance is part of the government’s continuing efforts to reduce the financial burden on patients, particularly those managing chronic and serious conditions.
The circular also states that the updated list replaces earlier issuances on VAT-exempt medicines and will remain in effect until revised by the FDA.